TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. (Q54529505)

31 May 2018

title

TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. (English)

1 reference

31 May 2018

1 reference

1 reference

31 May 2018

J. Silvio Gutkind

1 reference

31 May 2018

author name string

C Sun

1 reference

31 May 2018

A Dobi

1 reference

31 May 2018

A Mohamed

1 reference

31 May 2018

H Li

1 reference

31 May 2018

R L Thangapazham

1 reference

31 May 2018

S Shaheduzzaman

1 reference

31 May 2018

S-H Tan

1 reference

31 May 2018

G Vaidyanathan

1 reference

31 May 2018

E Whitman

1 reference

31 May 2018

D J Hawksworth

1 reference

31 May 2018

Y Chen

1 reference

31 May 2018

M Nau

1 reference

31 May 2018

V Patel

1 reference

31 May 2018

M Vahey

1 reference

31 May 2018

T Sreenath

1 reference

31 May 2018

G Petrovics

1 reference

31 May 2018

I A Sesterhenn

1 reference

31 May 2018

D G McLeod

1 reference

31 May 2018

S Srivastava

1 reference

31 May 2018

language of work or name

English

0 references

publication date

9 June 2008

1 reference

31 May 2018

published in

Oncogene

1 reference

31 May 2018

volume

1 reference

31 May 2018

issue

1 reference

31 May 2018

page(s)

5348-5353

1 reference

31 May 2018

High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

Inflammation in prostate carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

TMPRSS2-ETS fusion prostate cancer: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

A causal role for ERG in neoplastic transformation of prostate epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

New androgen receptor genomic targets show an interaction with the ETS1 transcription factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

Sequences in the human c-myc P2 promoter affect the elongation and premature termination of transcripts initiated from the upstream P1 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

Detailed mapping of the ERG-ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

The next generation of literature analysis: integration of genomic analysis into text mining

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

Disrupting insulin-like growth factor signaling as a potential cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

Role of the TMPRSS2-ERG gene fusion in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

ETS transcription factors and their emerging roles in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

Silencing of Lactotransferrin expression by methylation in prostate cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

Multiple prostate cancer risk variants on 8q24

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.183

VCaP, a cell-based model system of human prostate cancer

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18542058

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18542058

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/ONC.2008.183

1 reference

31 May 2018

PMC publication ID

7556723

0 references

1 reference

31 May 2018